<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00089843</url>
  </required_header>
  <id_info>
    <org_study_id>5 R01 DK052625 (completed)</org_study_id>
    <secondary_id>R01DK052625</secondary_id>
    <secondary_id>1UL1RR025758</secondary_id>
    <nct_id>NCT00089843</nct_id>
  </id_info>
  <brief_title>Bone Loss in Women With Anorexia Nervosa</brief_title>
  <official_title>IGF-1 and Bone Loss in Women Anorexia Nervosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women with Anorexia Nervosa have been found to have low bone density. The study will
      determine whether administration of low doses of a natural hormone, testosterone and/or
      risedronate, a medication to help prevent bone breakdown will improve or prevent bone loss in
      this condition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      II. SPECIFIC AIMS

      Severe osteopenia is a prevalent complication of anorexia nervosa (AN), affecting over half
      of all women with this disease. Loss of 25-50% of total bone mass occurs frequently and is
      often permanent. Although anorexia nervosa affects from 0.5-1.0% of college age women, no
      successful therapeutic interventions have been developed for osteoporosis in this population.
      Bone loss in anorexia nervosa is characterized by reduced bone formation coupled with
      increased bone resorption. Anorexia nervosa results in a deficiency of testosterone.
      Testosterone administration reduces bone resorption and data suggest that low-dose
      testosterone replacement therapy can increase surrogate markers of bone formation.
      Bisphosphonates are now well established to decrease bone resorption and improve bone density
      in severely osteopenic postmenopausal women. However, there are few data regarding the use of
      this antiresorptive therapy in women with severe pre-menopausal bone loss. Our preliminary
      data demonstrate that administration of a bisphosphonate decreases bone resorption and
      increases bone mass in women with AN after 6 and 9 months. These are the first data to
      demonstrate a striking increase in bone density in such women. We will test the hypothesis
      that a combined strategy to increase bone formation and decrease bone resorption by combining
      testosterone with a bisphosphonate will increase bone mass in anorexia nervosa.

      The following hypotheses will be tested:

      Specific Aim 1. Testosterone, a nutritionally dependent bone trophic factor, is a critical
      determinant of decreased bone formation in anorexia nervosa, and administration of
      physiologic testosterone will increase bone formation and lean body mass in this disease

      We will investigate in women with anorexia nervosa whether:

      A. Bone formation is reduced in association with low serum testosterone B. Testosterone
      deficiency is due to a combination of ovarian and adrenal defects resulting from
      undernutrition C. Testosterone administration reverses testosterone deficiency leading to an
      acute and sustained increase in bone formation and a decrease in bone resorption D.
      Administration of physiologic testosterone replacement stimulates increases in IGF-I levels
      in women with anorexia nervosa, a mechanism for increased bone formation and bone density E.
      Administration of physiologic testosterone replacement increases lean body mass, a major
      determinant of bone density

      Specific Aim 2. Long-term (12 months) physiologic testosterone administration combined with a
      bisphosphonate increases bone density by a dual anabolic and anti-resorptive strategy

      We will investigate in women with anorexia nervosa whether:

      A. Physiologic testosterone administration increases bone density B. Administration of a
      bisphosphonate decreases the excessive state of bone resorption and increases bone density C.
      Co-administration of physiologic testosterone replacement and a bisphosphonate increases bone
      density to a greater degree than testosterone or a bisphosphonate alone by increasing bone
      formation and decreasing bone resorption
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Mineral Density</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Percent change in postero-anterior (PA) spine bone mineral density as measured by dual energy x-ray absorptiometry (DXA)over a 12-month period. The differences in log-transformed values are reported as percent change.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Markers of Bone Metabolism</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>type 1 collagen C-telopeptide(CTX); The differences in log-transformed values are reported as percent change.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Anorexia Nervosa</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo Actonel (risedronate) and active testosterone patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Actonel (risedronate) and active testosterone patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Actonel (risedronate) and placebo testosterone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo testosterone patch and placebo Actonel (risedronate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>Testosterone patch 150mcg daily</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Intrinsa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Actonel (risedronate)</intervention_name>
    <description>Actonel (risedronate) 35mg PO one time weekly</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>Actonel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Actonel (risedronate)</intervention_name>
    <description>Placebo tablet identical in appearance to active Actonel (risedronate) tablet</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo testosterone</intervention_name>
    <description>Placebo patch identical in appearance to testosterone patch</description>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Anorexia Nervosa,

          -  Over 18,

          -  Female,

          -  Decreased bone density

        Exclusion Criteria:

          -  Medications to increase bone density
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Klibanski, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2004</study_first_submitted>
  <study_first_submitted_qc>August 16, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2004</study_first_posted>
  <results_first_submitted>November 9, 2011</results_first_submitted>
  <results_first_submitted_qc>May 1, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 1, 2012</results_first_posted>
  <last_update_submitted>May 1, 2012</last_update_submitted>
  <last_update_submitted_qc>May 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Anne Klibanski, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Eating Disorders</keyword>
  <keyword>Osteopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Risedronate Sodium</mesh_term>
    <mesh_term>Etidronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Actonel and Active Testosterone Patch</title>
          <description>Placebo Actonel tablet weekly and active testosterone patch (starting dose 150 mcg daily; increased to 300 mcg daily in subjects whose levels remained below the median on the initial dose)</description>
        </group>
        <group group_id="P2">
          <title>Active Actonel and Active Testosterone Patch</title>
          <description>Active Actonel tablet (35 mg weekly) and Active Testosterone patch (starting dose 150 mcg daily; increased to 300 mcg daily in subjects whose levels remained below the median on the initial dose)</description>
        </group>
        <group group_id="P3">
          <title>Active Actonel and Placebo Testosterone</title>
          <description>Active Actonel tablet (35 mg weekly) and Placebo Testosterone Patch</description>
        </group>
        <group group_id="P4">
          <title>Placebo Testosterone Patch and Placebo Actonel</title>
          <description>Placebo Testosterone Patch and placebo Actonel tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Actonel and Active Testosterone Patch</title>
          <description>Placebo Actonel tablet weekly and active testosterone patch (starting dose 150 mcg daily; increased to 300 mcg daily in subjects whose levels remained below the median on the initial dose)</description>
        </group>
        <group group_id="B2">
          <title>Active Actonel and Active Testosterone Patch</title>
          <description>Active Actonel tablet (35 mg weekly) and Active Testosterone patch (starting dose 150 mcg daily; increased to 300 mcg daily in subjects whose levels remained below the median on the initial dose)</description>
        </group>
        <group group_id="B3">
          <title>Active Actonel and Placebo Testosterone</title>
          <description>Active Actonel tablet (35 mg weekly) and Placebo Testosterone Patch</description>
        </group>
        <group group_id="B4">
          <title>Placebo Testosterone Patch and Placebo Actonel</title>
          <description>Placebo Testosterone Patch and placebo Actonel tablet</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="18"/>
            <count group_id="B5" value="77"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.1" spread="7.3"/>
                    <measurement group_id="B2" value="25.2" spread="6.2"/>
                    <measurement group_id="B3" value="25.3" spread="6.3"/>
                    <measurement group_id="B4" value="26.9" spread="7.2"/>
                    <measurement group_id="B5" value="26.1" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bone Mineral Density</title>
        <description>Percent change in postero-anterior (PA) spine bone mineral density as measured by dual energy x-ray absorptiometry (DXA)over a 12-month period. The differences in log-transformed values are reported as percent change.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>1 subject was excluded from analysis. A factorial analysis was performed and determines the effect of each intervention separately, whether or not a subject received the 2nd intervention. Therefore, data from all 76 subjects who participated were used to determine the effect of each intervention on our endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Actonel (Risedronate) 35 mg Weekly</title>
            <description>Actonel (risedronate) 35 mg, 1 tablet weekly</description>
          </group>
          <group group_id="O2">
            <title>Testosterone</title>
            <description>Testosterone, initial dose 150 mcg transdermal daily, increased to 300 mcg daily in women with free testosterone levels below the median (n=25 women)</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density</title>
          <description>Percent change in postero-anterior (PA) spine bone mineral density as measured by dual energy x-ray absorptiometry (DXA)over a 12-month period. The differences in log-transformed values are reported as percent change.</description>
          <population>1 subject was excluded from analysis. A factorial analysis was performed and determines the effect of each intervention separately, whether or not a subject received the 2nd intervention. Therefore, data from all 76 subjects who participated were used to determine the effect of each intervention on our endpoints.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="1.8" upper_limit="4.6"/>
                    <measurement group_id="O2" value="-0.6" lower_limit="-2.0" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Factorial analysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>This p value was for the effect of Actonel (risedronate) on bone mineral density of the spine.</p_value_desc>
            <method>Factorial analysis</method>
            <param_type>Percent change between 0 and 12 months</param_type>
            <param_value>3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.8</ci_lower_limit>
            <ci_upper_limit>4.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Factorial analysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.41</p_value>
            <p_value_desc>This p value was for the effect of testosterone on bone mineral density of the spine.</p_value_desc>
            <method>Factorial analysis</method>
            <param_type>Percent change between 0 and 12 months</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Markers of Bone Metabolism</title>
        <description>type 1 collagen C-telopeptide(CTX); The differences in log-transformed values are reported as percent change.</description>
        <time_frame>Baseline to 12 months</time_frame>
        <population>1 subject was excluded from analysis. A factorial analysis was performed and determines the effect of each intervention separately, whether or not a subject received the 2nd intervention. Therefore, data from all 76 subjects who participated were used to determine the effect of each intervention on our endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Actonel (Risedronate)</title>
            <description>Actonel (risedronate) 35 mg tablet weekly</description>
          </group>
          <group group_id="O2">
            <title>Testosterone</title>
            <description>Testosterone patch(starting dose 150 mcg daily; increased to 300 mcg daily in subjects whose levels remained below the median on the initial dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Markers of Bone Metabolism</title>
          <description>type 1 collagen C-telopeptide(CTX); The differences in log-transformed values are reported as percent change.</description>
          <population>1 subject was excluded from analysis. A factorial analysis was performed and determines the effect of each intervention separately, whether or not a subject received the 2nd intervention. Therefore, data from all 76 subjects who participated were used to determine the effect of each intervention on our endpoints.</population>
          <units>percent change of CTX</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41" lower_limit="-65" upper_limit="-17"/>
                    <measurement group_id="O2" value="-11" lower_limit="-35" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Factorial analysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>This p value was for the effect of Actonel (risedronate).</p_value_desc>
            <method>Factorial analysis</method>
            <param_type>Percent change between 0 and 12 months</param_type>
            <param_value>-41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Factorial analysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.39</p_value>
            <p_value_desc>This p value was for the effect of testosterone.</p_value_desc>
            <method>Factorial analysis</method>
            <param_type>Percent change between 0 and 12 months</param_type>
            <param_value>-11</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Actonel and Active Testosterone Patch</title>
          <description>Placebo Actonel tablet weekly and active testosterone patch (starting dose 150 mcg daily; increased to 300 mcg daily in subjects whose levels remained below the median on the initial dose)</description>
        </group>
        <group group_id="E2">
          <title>Active Actonel and Active Testosterone Patch</title>
          <description>Active Actonel tablet (35 mg weekly) and Active Testosterone patch (starting dose 150 mcg daily; increased to 300 mcg daily in subjects whose levels remained below the median on the initial dose)</description>
        </group>
        <group group_id="E3">
          <title>Active Actonel and Placebo Testosterone</title>
          <description>Active Actonel tablet (35 mg weekly) and Placebo Testosterone Patch</description>
        </group>
        <group group_id="E4">
          <title>Placebo Testosterone Patch and Placebo Actonel</title>
          <description>Placebo Testosterone Patch and placebo Actonel tablet</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization related to underlying condition (anorexia nervosa)</sub_title>
                <counts group_id="E1" events="16" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" events="11" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="13" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Reflux</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="11" subjects_affected="6" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgias</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Mild irritation at patch site</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="18" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E2" events="27" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E3" events="29" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E4" events="15" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Mild increase in acne or oily skin</sub_title>
                <counts group_id="E1" events="21" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E2" events="28" subjects_affected="13" subjects_at_risk="20"/>
                <counts group_id="E3" events="33" subjects_affected="13" subjects_at_risk="20"/>
                <counts group_id="E4" events="33" subjects_affected="12" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Mild increase in body hair growth</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E4" events="14" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anne Klibanski, M.D.</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-3870</phone>
      <email>aklibanski@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

